Conditions

HBOT is approved by FDA and UHMS and it is recognised for treating grafts, burns, infections, radiation injuries, and tissue necrosis. HBOT enhances post-surgical recovery through improved oxygenation, reduced swelling and inflammation, and increased collagen production, benefiting even those without complications.

Timely diagnosis and management, the effective use of HBOT in combination with standard ENT therapies are crucial to improve the possibility of regaining hearing.

Ageing is characterised by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death. This deterioration is the primary risk factor for major human pathologies, including cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases.

Breast cancer, a widely prevalent and devastating disease impacting millions of women globally, frequently necessitates mastectomy as a pivotal treatment approach. Mastectomy serves as a crucial surgical intervention that is essential in eliminating the disease and mitigating the risk of recurrence, ultimately enhancing patient survival outcomes.

In the UK, it is estimated that over 3 million individuals currently live with cancer. Radiotherapy is an essential part of cancer treatment, leading to 40% of global cancer remissions as well as improving the quality of life for many others patient affected by cancer. Unfortunately, radiation does not just destroy or inhibit the proliferation of cancer cells, but it can also impact neighbouring normal cells.

Idiopathic sudden sensorineural hearing loss is characterised by a rapid onset of auditory impairment, typically exceeding 30 decibels (dB) across three sequential frequencies within 72 hours. While not life-threatening, it has a significant impact on the quality of life of those affected. The annual occurrence of ISSNHL varies from 5 to 27 per 100,000 individuals, with around 66,000 new cases documented in the United States alone

Inflammatory bowel disease, the main types comprising Crohn’s disease and ulcerative colitis, is a debilitating chronic illness that affects millions of people worldwide. Though there are various therapies available for its treatment, many patients still struggle to control their symptoms and achieve remission. Recently, hyperbaric oxygen therapy (HBOT) has gained increasing interest as a treatment option for inflammatory bowel disease due to its potential, safety and efficacy.

Facial fillers have become more popular in recent years due to their non-invasive nature. Nevertheless, one of the most concerning risks associated with their use is necrosis caused by vascular obstruction. This potential complication may occur with several soft tissue fillers, but it is a rare occurrence, happening in only approximately 0.001% of procedures.

Discover how hyperbaric oxygen therapy (HBOT) can rejuvenate skin by reducing signs of aging. A recent clinical trial highlights HBOT's ability to decrease senescent cells, increase elastic fiber length, enhance collagen density, and induce angiogenesis, offering a promising pathway for skin care.

NUMA uses Monoplace hyperbaric chambers, which are designed to accommodate only one patient at a time. The hyperbaric chambers are compressed with air, and oxygen is given through facial masks.